ATTENUATED MEASLES VIRUS USED AS AN ONCOLYTIC VIRUS ACTIVATES MYELOID AND PLASMACYTOID DENDRITIC CELLS

Tuesday, 2nd of July 2013 Print
[source]Oncoimmunology[|source]

Jean-François Fonteneau et al present data which shows that attenuated strains of measles virus induce an immunogenic cell death of tumor cells capable of activating myeloid and plasmacytoid dendritic cells. Their study also shows that attenuated measles virus infection allows the release of tumor antigens for cross-presentation by both subsets of dendritic cells. Then they conclude that attenuated measles virus are promising antitumor agents with interesting effects on the antitumor immune response. More details available at:  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667908/

 

 

Abstract

Attenuated measles viruses (MV) are assessed in clinical trials for their capacity to preferentially infect and kill tumor cells. We recently showed that MV-infected tumor cells are able to activate tumor antigen cross-presentation by myeloid and plasmacytoid dendritic cells. Thus, MV-based antitumor virotherapy may stimulate antitumor immune response.

Special Postings

;

Highly Accessed

Website Views

47458330